Baura G D, Foster D M, Kaiyala K, Porte D, Kahn S E, Schwartz M W
Department of Bioengineering, University of Washington, Seattle, USA.
Diabetes. 1996 Jan;45(1):86-90. doi: 10.2337/diab.45.1.86.
We have previously shown that transport of plasma insulin into the central nervous system (CNS) is mediated by a saturable mechanism consistent with insulin binding to blood-brain barrier insulin receptors and subsequent transcytosis through microvessel endothelial cells. Since glucocorticoids antagonize insulin receptor-mediated actions both peripherally and in the CNS, we hypothesized that glucocorticoids also impair CNS insulin transport. Nine dogs were studied both in the control condition and after 7 days of high-dose oral dexamethasone (DEX) administration (12 mg/day) by obtaining plasma and cerebrospinal fluid (CSF) samples over 8 h for determination of immunoreactive insulin levels during a 90-min euglycemic intravenous insulin infusion (plasma insulin approximately 700 pmol/l). From these data, the kinetics of CNS insulin uptake and removal were determined using a mathematical model with three components (plasma-->intermediate compartment, hypothesized to be brain interstitial fluid-->CSF). DEX increased basal insulin levels 75% from 24 +/- 6 to 42 +/- 30 pmol/l (P < 0.005) and slightly increased basal glucose levels from 5.0 +/- 0.7 to 5.3 +/- 1.0 mmol/l (P < 0.05). DEX also lowered the model rate constant characterizing CNS insulin transport by 49% from 5.3 x 10(-6) +/- 4.0 x 10(-6) to 2.7 x 10(-6) +/- 1.2 x 10(-6) min-2 (P < or = 0.001). As glucocorticoids are known to reduce CSF turnover, we also hypothesized that the model rate constant associated with CSF insulin removal would be decreased by DEX. As expected, the model rate constant for CSF insulin removal decreased 47% from 0.038 +/- 0.013 to 0.020 +/- 0.088 min-1 (P < or = 0.0005) during DEX treatment. We conclude that DEX impairs CNS insulin transport. This finding supports our hypothesis that insulin receptors participate in the CNS insulin transport process and that this process may be subject to regulation. Moreover, since increasing brain insulin transport reduces food intake and body adiposity, this observation provides a potential mechanism by which glucocorticoid excess leads to increased body adiposity.
我们之前已经表明,血浆胰岛素向中枢神经系统(CNS)的转运是由一种可饱和机制介导的,这与胰岛素与血脑屏障胰岛素受体结合以及随后通过微血管内皮细胞的转胞吞作用一致。由于糖皮质激素在外周和中枢神经系统中均拮抗胰岛素受体介导的作用,我们推测糖皮质激素也会损害中枢神经系统胰岛素的转运。对9只犬在对照状态下以及在高剂量口服地塞米松(DEX)给药7天(12毫克/天)后进行了研究,通过在90分钟的正常血糖静脉胰岛素输注(血浆胰岛素约700皮摩尔/升)期间的8小时内采集血浆和脑脊液(CSF)样本,以测定免疫反应性胰岛素水平。根据这些数据,使用具有三个组分(血浆→中间隔室,假定为脑间质液→脑脊液)的数学模型来确定中枢神经系统胰岛素摄取和清除的动力学。DEX使基础胰岛素水平从24±6皮摩尔/升增加75%至42±30皮摩尔/升(P<0.005),并使基础葡萄糖水平从5.0±0.7毫摩尔/升轻微增加至5.3±1.0毫摩尔/升(P<0.05)。DEX还使表征中枢神经系统胰岛素转运的模型速率常数降低49%,从5.3×10⁻⁶±4.0×10⁻⁶降至2.7×10⁻⁶±1.2×10⁻⁶分钟⁻²(P≤0.001)。由于已知糖皮质激素会减少脑脊液的更新,我们还推测与脑脊液胰岛素清除相关的模型速率常数会因DEX而降低。正如预期的那样,在DEX治疗期间,脑脊液胰岛素清除的模型速率常数从0.038±0.013降至0.020±0.088分钟⁻¹,降低了47%(P≤0.0005)。我们得出结论,DEX会损害中枢神经系统胰岛素的转运。这一发现支持了我们的假设,即胰岛素受体参与中枢神经系统胰岛素转运过程,并且该过程可能受到调节。此外,由于增加脑胰岛素转运会减少食物摄入和身体脂肪,这一观察结果提供了一种潜在机制,通过该机制糖皮质激素过量会导致身体脂肪增加。